Zhiyi Pharmaceutics is focused on the research and development of innovative microbiome-based therapies, specifically in the field of digestion. The company specializes in next-generation probiotics (NGPs) and live biotherapeutics (LBPs), which are designed to enhance gut health and address various digestive disorders. By leveraging advanced scientific methodologies, Zhiyi aims to create effective therapeutic solutions that harness the power of beneficial microorganisms to improve patient outcomes.

The company’s commitment to innovation in the microbiome space positions it as a leader in the development of live biotherapeutics. These therapies are characterized by their use of live microorganisms to treat or prevent diseases, offering a promising alternative to traditional pharmaceuticals. Zhiyi Pharmaceutics is dedicated to advancing the understanding and application of these technologies, contributing to the growing field of microbiome research and its potential to revolutionize digestive health treatments.

China

Zhiyi is a leading company in live biotherapeutics (LBPs) and next-generation probiotics in China. The company’s SK08（Bacteroides fragilis） was approved for clinical trials in November 2019.It is the first LBP in China with immense influence. Zhiyi has established a complete technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients. Zhiyi also has a complete industrialization platform from preclinical to NDA.

Zhiyi Pharmaceutics

Company Details